TriangleDISEASE & TREATMENT SETTING
Cutaneous T-Cell Lymphomas
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Cutaneous T-Cell Lymphomas
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- clinically-proposed
- derivation note
- Derived from NCI topic(s): Mycosis Fungoides and Other Cutaneous T-Cell Lymphomas. Strongest NCIt resolution: candidate. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
11 more-specific settings
Ontak: recurrent Cutaneous T-cell lymphoma →ZOLINZA: recurrent Cutaneous T-cell lymphoma after prior therapy →VALCHLOR: Cutaneous T-cell lymphoma after prior therapy →LYMPHIR: refractory Cutaneous T-cell lymphoma after prior therapy →VALCHLOR: Cutaneous T-cell lymphoma after prior therapy →ISTODAX: Cutaneous T-cell lymphoma after prior therapy →Targretin: refractory Cutaneous T-cell lymphoma →ISTODAX: Cutaneous T-cell lymphoma after prior therapy →Stage I Cutaneous T-Cell Lymphomas →Stage III Cutaneous T-Cell Lymphomas →recurrent Cutaneous T-Cell Lymphomas →
Study evidence for this setting
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantl
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignanc
Indication-specific source history
1999-02-05 · Ontak (denileukin diftitox) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-cutaneous-t-cell-lymphomas
- event id
- fda-c7a4b54ebe15cc44
- event date
- 1999-02-05
- event kind
- accelerated-approval
- drug or regimen
- Ontak (denileukin diftitox)
- source indication text
- Persistent or recurrent cutaneous T-cell lymphoma expressing the CD25 component of IL-2 receptor
- match phrase
- cutaneous t-cell lymphoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-daaeddd872d2149f1855
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2008-10-15 · Ontak (denileukin diftitox) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-cutaneous-t-cell-lymphomas
- event id
- fda-2d6220c216f291d9
- event date
- 2008-10-15
- event kind
- traditional-approval
- drug or regimen
- Ontak (denileukin diftitox)
- source indication text
- Persistent or recurrent cutaneous T-cell lymphoma expressing the CD25 component of IL-2 receptor
- match phrase
- cutaneous t-cell lymphoma
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-daaeddd872d2149f1855
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-cutaneous-t-cell-lymphomas
- binding id
- ncit-C3467
- source collection
- ncit-concept
- source key
- C3467
- source excerpt
- Source null
- match status
- candidate
- match note
- Resolution status: candidate.
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice